Nickel-catalyzed divergent sulfonations of propargylic carbonate.

Wenfeng Gu, Zhuozhuo He, Haiyang Wang, Lingzi Peng, Chang Guo

Abstract read

In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Catalytic Enantioselective Construction of Carbon-Sulfur Bonds: Recent Advances and Future Perspectives.Molecules (Basel, Switzerland) · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wenfeng Gu *Hefei National Research Center for Physical Sciences at the Microscale and Department of Chemistry, University of Science and Technology of China, Hefei, China.

Zhuozhuo He *Hefei National Research Center for Physical Sciences at the Microscale and Department of Chemistry, University of Science and Technology of China, Hefei, China.

Haiyang Wang *Hefei National Research Center for Physical Sciences at the Microscale and Department of Chemistry, University of Science and Technology of China, Hefei, China.

Lingzi PengHefei National Research Center for Physical Sciences at the Microscale and Department of Chemistry, University of Science and Technology of China, Hefei, China.ORCID http://orcid.org/0000-0001-5180-8040

Chang GuoHefei National Research Center for Physical Sciences at the Microscale and Department of Chemistry, University of Science and Technology of China, Hefei, China. guochang@ustc.edu.cn.ORCID http://orcid.org/0000-0003-4022-9582

Funding

National Natural Science Foundation of China (National Science Foundation of China) 21971227

6 · The paper itself

Abstract

Chiral sodium sulfinates serve as crucial synthetic intermediates utilized for rapidly producing a variety of enantioenriched sulfone derivatives that are pervasive in the fields of pharmaceutical chemistry and chemical synthesis. Here we present a practical and highly effective method for the nickel-catalyzed asymmetric sulfonation of propargylic carbonates for the production of essential synthetic building blocks. Notably, sodium 1-methyl 3-sulfinopropanoate (SMOPS), a commercially available sulfonylation reagent, has potential for in situ unmasking and functionalization in the formation of enantioenriched sulfinate salts for diverse product diversification. With operational simplicity and remarkable tolerance toward diverse functional groups, this methodology provides an extensive collection of biologically relevant propargylated, allenylated, and 1,3-dienylated sulfones, with excellent yields and regio- and stereoselectivities.

Identifiers

PMID41559105

DOI10.1038/s41467-026-68720-w

PMCPMC12923841

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.